Actively Recruiting
Cohorte Nantaise de Maladies Inflammatoires Chroniques Intestinales
Led by Nantes University Hospital · Updated on 2025-02-10
360
Participants Needed
3
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting the CELESTE cohort study, a prospective observational research project involving patients with Inflammatory Bowel Diseases (IBD). The study is set across three centers in Nantes, including a tertiary referral center and two secondary care centers. It aims to include a broad range of patients with active IBD, such as Crohn's disease, ulcerative colitis, unclassified IBD, or chronic pouchitis, to identify new cellular and molecular markers that may predict treatment success after one year. Participants will undergo collection of biological samples, including blood and intestinal biopsies, during surgery or colonoscopy performed for disease relapse. This sampling is part of a multi-omics biobank associated with the cohort, which supports detailed analysis of disease and treatment responses. Patients included may be treatment-naïve or refractory to multiple biologic therapies. During the study, patients will be followed for one year to assess the proportion who succeed in their therapeutic strategy. Researchers will use biological samples and clinical data collected at diagnosis or before starting new therapies to understand treatment outcomes. Participation involves scheduled consultations, surgeries, or colonoscopies as part of usual care, with no additional experimental treatments. The study continues through February 2031, with ongoing monitoring of patient progress and sample analysis.
CONDITIONS
Brief Title
Inflammatory Bowel Disease Cohort in Nantes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Patients with an established diagnosis of IBD: Crohn's disease, ulcerative colitis, unclassified IBD, or refractory chronic pouchitis
- Patients with active disease requiring surgery or endoscopy, performed at diagnosis or before starting new therapy
- Patients who have provided written consent to participate and allow storage of biological samples for research
You will not qualify if you...
- Patients refusing to participate in the cohort
- Patients with inactive (quiescent) chronic inflammatory bowel disease at inclusion
- Patients with contraindications to general anesthesia
- Vulnerable patients under court protection, curators, or guardians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At disease relapse or prior to starting new therapy
Participants undergo surgery or colonoscopy for disease relapse to collect biological samples such as blood and intestinal biopsies.
1 to 2 visits depending on clinical need
Duration - Up to 1 year after inclusion
Participants are followed up over time to observe the success of their therapeutic strategy and disease progression.
Periodic follow-up visits over one year
Trial Site Locations
Total: 3 locations
1
CHU de Nantes
Nantes, France
Actively Recruiting
2
Clinique Jules Verne
Nantes, France
Not Yet Recruiting
3
Hopital Privé du Confluent
Nantes, France
Not Yet Recruiting
Research Team
C
Catherine Le Berre, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here